374 related articles for article (PubMed ID: 26802582)
1. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.
Vantaku V; Dong J; Ambati CR; Perera D; Donepudi SR; Amara CS; Putluri V; Ravi SS; Robertson MJ; Piyarathna DWB; Villanueva M; von Rundstedt FC; Karanam B; Ballester LY; Terris MK; Bollag RJ; Lerner SP; Apolo AB; Villanueva H; Lee M; Sikora AG; Lotan Y; Sreekumar A; Coarfa C; Putluri N
Clin Cancer Res; 2019 Jun; 25(12):3689-3701. PubMed ID: 30846479
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
5. Integration of metabolomic and transcriptomic data reveals metabolic pathway alteration in breast cancer and impact of related signature on survival.
Luo X; Yu H; Song Y; Sun T
J Cell Physiol; 2019 Aug; 234(8):13021-13031. PubMed ID: 30556899
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
8. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
9. A novel clinical multidimensional transcriptome signature predicts prognosis in bladder cancer.
Liu CP; Zhang JH; Zheng SC; Liu J; Guo JC
Oncol Rep; 2018 Nov; 40(5):2826-2835. PubMed ID: 30226624
[TBL] [Abstract][Full Text] [Related]
10. Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival.
Amara CS; Ambati CR; Vantaku V; Badrajee Piyarathna DW; Donepudi SR; Ravi SS; Arnold JM; Putluri V; Chatta G; Guru KA; Badr H; Terris MK; Bollag RJ; Sreekumar A; Apolo AB; Putluri N
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):770-781. PubMed ID: 30642841
[TBL] [Abstract][Full Text] [Related]
11. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA.
Wang Y; Chen W; Li K; Wu G; Zhang W; Ma P; Feng S
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34549263
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
13. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.
Xiong J; Xiong K; Bing Z
Cancer Biomark; 2018 Feb; 21(3):535-546. PubMed ID: 29226853
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
[TBL] [Abstract][Full Text] [Related]
15. Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma.
Luo Q; Zhang X
Biomed Res Int; 2020; 2020():7147824. PubMed ID: 32802870
[TBL] [Abstract][Full Text] [Related]
16. Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder.
Kuang S; Li H; Feng J; Xu S; Le Y
Cancer Biomark; 2019; 25(2):203-212. PubMed ID: 31045513
[TBL] [Abstract][Full Text] [Related]
17. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients.
Sun Z; Jing C; Xiao C; Li T
Aging (Albany NY); 2020 Aug; 12(15):15624-15637. PubMed ID: 32805727
[TBL] [Abstract][Full Text] [Related]
18. Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder.
Piyarathna DWB; Rajendiran TM; Putluri V; Vantaku V; Soni T; von Rundstedt FC; Donepudi SR; Jin F; Maity S; Ambati CR; Dong J; Gödde D; Roth S; Störkel S; Degener S; Michailidis G; Lerner SP; Pennathur S; Lotan Y; Coarfa C; Sreekumar A; Putluri N
Eur Urol Focus; 2018 Dec; 4(6):907-915. PubMed ID: 28753886
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
Sanford T; Meng MV; Railkar R; Agarwal PK; Porten SP
Clin Epigenetics; 2018; 10():19. PubMed ID: 29456764
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
